These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1127 related items for PubMed ID: 24475976

  • 41. Coinfection rates and clinical outcome data for cytomegalovirus and Epstein-Barr virus in post-transplant patients: A systematic review of the literature.
    Anderson-Smits C, Baker ER, Hirji I.
    Transpl Infect Dis; 2020 Dec; 22(6):e13396. PubMed ID: 32603496
    [Abstract] [Full Text] [Related]

  • 42. CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation.
    Orjuela MA, Alobeid B, Liu X, Siebert AL, Kott ER, Addonizio LJ, Morris E, Garvin JH, Lobritto SJ, Cairo MS.
    Br J Haematol; 2011 Mar; 152(6):733-42. PubMed ID: 21275950
    [Abstract] [Full Text] [Related]

  • 43. Induction of pre-transplant Epstein-Barr virus (EBV) infection by donor blood transfusion in EBV-seronegative recipients may reduce risk of post-transplant lymphoproliferative disease in adolescent renal transplant patients: report of two cases.
    Babel N, Gabdrakhmanova L, Hammer M, Rosenberger C, Oppert M, Volk HD, Reinke P.
    Transpl Infect Dis; 2005 Mar; 7(3-4):133-6. PubMed ID: 16390402
    [Abstract] [Full Text] [Related]

  • 44. Managing the challenge of PTLD in liver and bowel transplant recipients.
    Lauro A, Arpinati M, Pinna AD.
    Br J Haematol; 2015 Apr; 169(2):157-72. PubMed ID: 25377273
    [Abstract] [Full Text] [Related]

  • 45. Epstein-Barr virus-associated post-transplant lymphoproliferative disorders in pediatric transplantation: A prospective multicenter study in the United States.
    Tajima T, Martinez OM, Bernstein D, Boyd SD, Gratzinger D, Lum G, Sasaki K, Tan B, Twist CJ, Weinberg K, Armstrong B, Desai DM, Mazariegos GV, Chin C, Fishbein TM, Tekin A, Venick RS, Krams SM, Esquivel CO.
    Pediatr Transplant; 2024 Jun; 28(4):e14763. PubMed ID: 38682750
    [Abstract] [Full Text] [Related]

  • 46. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation.
    Taylor AL, Marcus R, Bradley JA.
    Crit Rev Oncol Hematol; 2005 Oct; 56(1):155-67. PubMed ID: 15979320
    [Abstract] [Full Text] [Related]

  • 47. Risk factors for post-transplant Epstein-Barr virus events in pediatric recipients of hematopoietic stem cell transplants.
    Enok Bonong PR, Buteau C, Duval M, Lacroix J, Laporte L, Tucci M, Robitaille N, Spinella PC, Cuvelier GDE, Lewis V, Vercauteren S, Alfieri C, Trottier H.
    Pediatr Transplant; 2021 Nov; 25(7):e14052. PubMed ID: 34076939
    [Abstract] [Full Text] [Related]

  • 48. Early evidence of lymphoproliferative disorder: post-transplant monitoring of Epstein-Barr infection in adult and pediatric patients.
    Gaeta A, Nazzari C, Verzaro S, Latte MC, Fabri G, Scateni S, Raggi C, Lubrano R, Mancini C.
    New Microbiol; 2006 Oct; 29(4):231-41. PubMed ID: 17201089
    [Abstract] [Full Text] [Related]

  • 49. New developments in the diagnosis and management of posttransplantation lymphoproliferative disorders in solid organ transplant recipients.
    Preiksaitis JK.
    Clin Infect Dis; 2004 Oct 01; 39(7):1016-23. PubMed ID: 15472855
    [Abstract] [Full Text] [Related]

  • 50. Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.
    Patel C, Pasciolla M, Abramova R, Salerno D, Gomez-Arteaga A, Shore TB, Orfali N, Mayer S, Hsu J, Phillips AA, Chaekal OK, Satlin MJ, Soave R, Kodiyanplakkal RPL, Drelick A, Plate M, Besien KV.
    Transplant Cell Ther; 2023 Feb 01; 29(2):132.e1-132.e5. PubMed ID: 36334653
    [Abstract] [Full Text] [Related]

  • 51. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients.
    Lee TC, Savoldo B, Barshes NR, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Scott JD, Goss JA.
    Clin Transplant; 2006 Feb 01; 20(3):389-93. PubMed ID: 16824159
    [Abstract] [Full Text] [Related]

  • 52. Association between Epstein-Barr virus seroconversion and immunohistochemical changes in tonsils of pediatric solid organ transplant recipients.
    Shapiro NL, Tang CG, Bhattacharyya N.
    Laryngoscope; 2011 Aug 01; 121(8):1718-25. PubMed ID: 21792960
    [Abstract] [Full Text] [Related]

  • 53. Post-transplant lymphoproliferative disorders.
    Singavi AK, Harrington AM, Fenske TS.
    Cancer Treat Res; 2015 Aug 01; 165():305-27. PubMed ID: 25655616
    [Abstract] [Full Text] [Related]

  • 54. Expert Consensus on the Characteristics of Patients with Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) for Whom Standard-Dose Chemotherapy May be Inappropriate: A Modified Delphi Study.
    Chaganti S, Barlev A, Caillard S, Choquet S, Cwynarski K, Friedetzky A, González-Barca E, Sadetsky N, Schneeberger S, Thirumalai D, Zinzani PL, Trappe RU.
    Adv Ther; 2023 Mar 01; 40(3):1267-1281. PubMed ID: 36681739
    [Abstract] [Full Text] [Related]

  • 55. The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients.
    Green M, Michaels MG, Webber SA, Rowe D, Reyes J.
    Pediatr Transplant; 1999 Nov 01; 3(4):271-81. PubMed ID: 10562971
    [Abstract] [Full Text] [Related]

  • 56. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
    Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW.
    J Clin Oncol; 2009 Jul 10; 27(20):3354-62. PubMed ID: 19451438
    [Abstract] [Full Text] [Related]

  • 57. Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab.
    Patriarca F, Medeot M, Isola M, Battista ML, Sperotto A, Pipan C, Toffoletti E, Dozzo M, Michelutti A, Gregoraci G, Geromin A, Cerno M, Savignano C, Rinaldi C, Barbone F, Fanin R.
    Transpl Infect Dis; 2013 Jun 10; 15(3):259-67. PubMed ID: 23405972
    [Abstract] [Full Text] [Related]

  • 58. Dynamic EBV gene loads in renal, hepatic, and cardiothoracic transplant recipients as determined by real-time PCR light cycler.
    Leung E, Shenton BK, Green K, Jackson G, Gould FK, Yap C, Talbot D.
    Transpl Infect Dis; 2004 Dec 10; 6(4):156-64. PubMed ID: 15762933
    [Abstract] [Full Text] [Related]

  • 59. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial.
    Mahadeo KM, Baiocchi R, Beitinjaneh A, Chaganti S, Choquet S, Dierickx D, Dinavahi R, Duan X, Gamelin L, Ghobadi A, Guzman-Becerra N, Joshi M, Mehta A, Navarro WH, Nikiforow S, O'Reilly RJ, Reshef R, Ruiz F, Spindler T, Prockop S.
    Lancet Oncol; 2024 Mar 10; 25(3):376-387. PubMed ID: 38309282
    [Abstract] [Full Text] [Related]

  • 60. A Scheduled Program of Molecular Screening for Epstein-Barr Virus Decreases the Incidence of Post-transplantation Lymphoproliferative Disease in Pediatric Liver Transplantation.
    Soriano-López DP, Alcántar-Fierros JM, Hernández-Plata JA, González-Jorge AL, Velázquez-Ramos S, Flores-Hernández MA, Fuentes V, Castañeda P, Nieto J, Sánchez JL, López B, Valencia-Mayoral P, Varela-Fascinetto G.
    Transplant Proc; 2016 Mar 10; 48(2):654-7. PubMed ID: 27110023
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 57.